Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanSino BiologicsCASBF 69 Net Margin % is 3.66% as of Dec. 2025. GuruFocus rates CASBF with a GF Score™ of 69/100 and a GF Value™ of $8.73 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 962 Drug Manufacturers companies, CanSino Biologics ranks better than 51.66% on this metric.
The historical rank and industry rank for CanSino Biologics's Net Margin % or its related term are showing as below:
CASBF'
s Net Margin % Range Over the Past 10 Years
Min: -12214.46 Med: -88.21 Max: 44.52
Current: 6.02
CASBF's Net Margin % is ranked better than 51.66% of 962
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs CASBF: 6.02
CanSino Biologics (OTCPK:CASBF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
CanSino Biologics Net Margin % Related Terms
CanSino Biologics Net Margin % Historical Data
* Premium members only.
The historical data trend for CanSino Biologics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanSino Biologics Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Net Margin % distribution charts can be found below:
* The bar in red indicates where CanSino Biologics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanSino Biologics (CASBF) has a Net Margin % of 3.66% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on CanSino Biologics and its competitors. According to the industry distribution chart, CanSino Biologics ranks #465 out of 962 companies in the Drug Manufacturers industry, placing it in the top 48.3%.
Is CanSino Biologics' Net Margin % too high?
CanSino Biologics' current Net Margin % is 3.66%. The Drug Manufacturers industry median Net Margin % is 5.56. CanSino Biologics' value of 3.66% is 34.2% below this industry median. Based on the distribution chart, CanSino Biologics ranks #465 out of 962 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, CanSino Biologics has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, CanSino Biologics ranks #465 out of 962 companies for Net Margin %. This puts CanSino Biologics in the upper half of its industry. The industry median Net Margin % is 5.56. CanSino Biologics' value of 3.66% is 34.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanSino Biologics's current Net Margin % of 3.66% is 34.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on CanSino Biologics and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanSino Biologics's current Net Margin % is 3.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (CASBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $8.73, compared to a current price of $2.60 — trading 70.2% below its estimated fair value. The current Net Margin % is 3.66% and 34.2% below the Drug Manufacturers industry median of 5.56. CanSino Biologics' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For CanSino Biologics (CASBF), the current Net Margin % is 3.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CanSino Biologics (CASBF) Overvalued in 2026?
Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued.
The current stock price of $2.60 is trading 70.2% below its estimated GF Value™ of $8.73.
GuruFocus considers CanSino Biologics to be Significantly Undervalued.
Key valuation signals for CASBF:
Net Margin %: 3.66%
GF Value™: $8.73 vs. price of $2.60 (70.2% below fair value)
Industry Position: 34.2% below the Drug Manufacturers median (#465 of 962)
No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
69GF Score
Get the complete analysis for CASBF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASBF has been successfully added to your 
